Literature DB >> 15878232

A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats.

Makiko Tsuzuki1, Wenwen Wu, Hiroyuki Nishikawa, Ryosuke Hayami, Daisuke Oyake, Yukari Yabuki, Mamoru Fukuda, Tomohiko Ohta.   

Abstract

BARD1 is a crucial partner of the breast and ovarian tumor suppressor BRCA1 required for ubiquitin ligase activity and for reciprocal stabilization in cells. We report here an alternatively spliced human BARD1 mRNA variant (BARD1DeltaRIN) isolated from a HeLa cell cDNA library. It is characterized by deletion of exons 2-6 that encode most of the RING finger domain and the entire span of ankyrin repeats. DeltaRIN transcript was detected in all breast cancer-cell lines studied although its protein expression level was low. DeltaRIN does not interact with BRCA1, whereas it interacts with and colocalizes with CstF-50 to cytoplasmic dots. Hence, a deletion variant of BARD1 occurs in cells and may play a distinct role with CstF-50.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 15878232     DOI: 10.1016/j.canlet.2005.03.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences.

Authors:  David Fox; Isolde Le Trong; Ponni Rajagopal; Peter S Brzovic; Ronald E Stenkamp; Rachel E Klevit
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

2.  Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.

Authors:  Apichart Atipairin; Bhutorn Canyuk; Adisorn Ratanaphan
Journal:  J Biol Inorg Chem       Date:  2010-10-22       Impact factor: 3.358

3.  BARD1 expression predicts outcome in colon cancer.

Authors:  Judith C Sporn; Torsten Hothorn; Barbara Jung
Journal:  Clin Cancer Res       Date:  2011-06-21       Impact factor: 12.531

4.  Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

Authors:  Kristopher R Bosse; Sharon J Diskin; Kristina A Cole; Andrew C Wood; Robert W Schnepp; Geoffrey Norris; Le B Nguyen; Jayanti Jagannathan; Michael Laquaglia; Cynthia Winter; Maura Diamond; Cuiping Hou; Edward F Attiyeh; Yael P Mosse; Vanessa Pineros; Eva Dizin; Yongqiang Zhang; Shahab Asgharzadeh; Robert C Seeger; Mario Capasso; Bruce R Pawel; Marcella Devoto; Hakon Hakonarson; Eric F Rappaport; Irmgard Irminger-Finger; John M Maris
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

Review 5.  Dualistic Role of BARD1 in Cancer.

Authors:  Flora Cimmino; Daniela Formicola; Mario Capasso
Journal:  Genes (Basel)       Date:  2017-12-08       Impact factor: 4.096

6.  Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability.

Authors:  Maxim Pilyugin; Pierre-Alain André; Magdalena Ratajska; Alina Kuzniacka; Janusz Limon; Benjamin B Tournier; Julien Colas; Geoff Laurent; Irmgard Irminger-Finger
Journal:  Oncotarget       Date:  2017-02-07

Review 7.  The Effects of Genetic and Epigenetic Alterations of BARD1 on the Development of Non-Breast and Non-Gynecological Cancers.

Authors:  Andrea K Watters; Emily S Seltzer; Danny MacKenzie; Melody Young; Jonathan Muratori; Rama Hussein; Andrej M Sodoma; Julie To; Manrose Singh; Dong Zhang
Journal:  Genes (Basel)       Date:  2020-07-21       Impact factor: 4.096

Review 8.  Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.

Authors:  Wejdan M Alenezi; Caitlin T Fierheller; Neil Recio; Patricia N Tonin
Journal:  Genes (Basel)       Date:  2020-07-27       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.